



Curriculum Vitae

Personal information **Fiorella Petronzelli**

Work experience

1. Employer: AIFA, Italian Medicines Agency
 - Start date: 042017
 - End date:
 - Position: Pharmacovigilance Senior Assessor
 - Activities: Scientific evaluation of PSUSA procedures, analysis of ADRs, vaccinovigilance activities, referral procedures, evaluation of safety variation procedures
 - Country: Italy
2. Employer: AIFA, Italian Medicines Agency
 - Start date: 072016
 - End date: 042017
 - Position: Quality Assessor, Biological Medicinal Products Assessment Office
 - Activities:

Scientific evaluation of national, MR or DC procedures of variations to marketing authorization of biological medicinal products
 - Country: Italy
3. Employer: Sigma_Tau SpA – Research and Development, Pomezia, Rome, Italy
 - Start date: 102007
 - End date: 062016
 - Position: Project Leader Biotech Products
 - Activities:

Coordination on in house and outsourced research activities on therapeutic monoclonal antibodies.

Support to process development at several CMOs and a Radiopharmacy.

Regulatory issues on quality of biotech products (EMA and ICH guidelines). Immunogenicity studies

Experience in a phase I/II Clinical Study (radiopharmaceutical antibody)
 - Country: Italy
4. Employer: Sigma_Tau SpA – Research and Development
 - Start date: 012012
 - End date: 012013
 - Position: Radio Immuno Pharmacology Laboratory Head
 - Activities:

Coordination of the group skilled in micromanipulation of rodents for in vivo radiopharmacology experiments
 - Country: Italy
5. Employer: Sigma_Tau SpA – Research and Development
 - Start date: 022003
 - End date: 102007
 - Position: Head of Hybridoma Laboratory
 - Activities:

Generation and characterization of murine monoclonal antibodies towards tumor antigens
 - Country: Italy
6. Employer: Sigma_Tau SpA – Research and Development
 - Start date: 022001
 - End date: 022003
 - Position: Staff scientist Immunobiochemistry Laboratory
 - Activities:

Basic research on Tenascin_C isoforms Surface Plasmon Resonance Unit set up
 - Country: Italy
7. Employer: Medical Genetics Institute, Catholic University of the Sacred Heart
 - Start date: 061998
 - End date: 102000
 - Position: Post Doc, Human Genetic Laboratory
 - Activities:

• Country: Italy
8. Employer: Fox Chase Cancer Center
 - Start date: 061999
 - End date: 032000
 - Position: Post Doc
 - Activities:

• Country: United States
9. Employer: Imperial Cancer Research Fund
 - Start date: 101993

- End date: 121994
 - Position: PhD student
 - Activities:
 - Country: United Kingdom
10. Employer: Experimental Medicine Department, "La Sapienza" University
- Start date: 021990
 - End date: 061998
 - Position: Graduate student, PhD Student
 - Activities:
 - Country: Italy

Education and training

1. Subject: "La Sapienza" University
 - Start date: 1997
 - End date: 2000
 - Qualification: Specialization school in Medical Genetics
 - Organisation:
 - Country: Italy
2. Subject: "La Sapienza" University
 - Start date: 1994
 - End date: 1997
 - Qualification: PhD Experimental Medicine
 - Organisation:
 - Country: Italy
3. Subject: "La Sapienza" University
 - Start date: 1992
 - End date: 1993
 - Qualification: Master in Medical Informatics
 - Organisation:
 - Country: Italy
4. Subject: "La Sapienza" University
 - Start date: 1987
 - End date: 1991
 - Qualification: Degree in Biological Sciences
 - Organisation:
 - Country: Italy

Additional information

Publications

1. Petronzelli F, P. Ferrante, P. Triglione, M. Bonamico, M.C. Mazzilli (1991) "Oligotyping of celiac multiplex families with the 11th International Histocompatibility Workshop reagents" *Tissue Antigens* 38: 238_239. 2. P. Ferrante, Petronzelli F, P. Mariani, M. Bonamico, M.C. Mazzilli (1992) "Oligotyping of Italian celiac patients with the 11th International Histocompatibility Workshop reagents" *Tissue Antigens*, 39: 38_39. 3. MC. Mazzilli, P. Ferrante, P. Mariani, E. Martone, Petronzelli F, P. Triglione, M. Bonamico (1992) "A study of Italian pediatric celiac disease patients confirms that the primary HLA association is to the DQ(α 1*0501, β 1*0201) heterodimer" *Human Immunology*, 33: 133_139. 4. Petronzelli F, G. Multari, P. Ferrante, M. Bonamico, G. Rabuffo, M.C. Mazzilli (1993) "Differences in the distribution of susceptible and protective HLA_DQA1/B1 genotypes in Italian IDDM and CD patients" *Hum. Immunol.*, 36: 156_162. 5. M. Bonamico, P. Mariani, P. Triglione, P. Lionetti, P. Ferrante, Petronzelli F, M. Morellini, M.C. Mazzilli (1994) "Celiac disease in two sisters with a mother from Cape Verde island. A clinical and genetic study" *J. Pediatr. Gastroenterol. Nutr.* 18: 96_99. 6. Sadler, Petronzelli F, P. Krausa, S.G.E. Marsh, M.G. Guttridge, M.J. Browning, J.G. Bodmer (1994) "Low resolution DNA typing for HLA_B using sequence_specific primers in allele_ or group_specific ARMS_PCR" *Tissue Antigens*, 44: 148_154. 7. Petronzelli F, A. Kimura, P. Ferrante, M.C. Mazzilli (1995) "Polymorphism in the upstream regulatory region of DQA1 gene in the Italian population" *Tissue Antigens* 45: 258_263. 8. P. Mariani, M.C. Mazzilli, G. Margutti, P. Triglione, Petronzelli F, E. Ferrante, M. Bonamico (1995) "Coeliac disease, emmanuel defects and HLA typing" *Acta Paediatrica* 83: 1272_75. 9. P. Ferrante, I. Apollonio, A. Del Nero, Petronzelli F, M.C. Mazzilli (1996) "Regulation of HLA genes expression" *Minerva Biotecnologica*, 8: 32_42. 10. R. Grillo, Petronzelli F, P. Ferrante, B. Mora, M. Bonamico, M.C. Mazzilli (1996) "Unusual HLA typing in Celiac Disease" *Disease Markers*, 13: 61_64. 11. M. Browning, Petronzelli F, D. Bicknell et al. (1996) "Mechanisms of loss of HLA class I expression on colorectal tumor cells" *Tissue Antigens* 47: 364_371. 12. B. Mora, Petronzelli F, R. Grillo, P. Ferrante, M.C. Mazzilli (1996) "Single Strand Conformation Polymorphism (SSCP) analysis of DRB1*1101_1106 alleles" *Eur. J. Immunogenetics*, 23: 345_352. 13. Petronzelli F, P. Ferrante, M. Bonamico, R. Grillo, B. Mora, P. Mariani, I. Apollonio, G. Gemme, M.C. Mazzilli (1997) "Genetic contribution of HLA region to the familial clustering of coeliac disease" *Annals of Human Genetics*, 61: 307_317. 14. P. Indovina, F. Megiorni, P. Ferrante, I. Apollonio, Petronzelli F, M.C. Mazzilli (1998) "Functional role of the Y_box polymorphism in the regulation of DQA1 gene transcription" *Hum. Immunol*, 59: 758_767. 15. R. Grillo, Petronzelli F, B. Mora, M. Bonamico, M.C. Mazzilli (2000) "Search for coeliac disease susceptibility loci on 7q11.23 candidate region: absence of association of the ELN17 microsatellite marker" *Human Heredity*, 50: 180_183. 16. Petronzelli F, A. Riccio, GD. Markham, SH. Seeholzer, AT. Yeung, Y. Matsumoto, J. Stoeker, M. Genuardi, A. Bellacosa (2000) "Investigation of the substrate spectrum of the human mismatch_specific DNA N_glycosylase MED1 (MBD4): fundamental role of the catalytic domain" *J. Cell Physiol.* 185: 473_80. 17. Petronzelli F, A. Riccio, GD. Markham, SH. Seeholzer, JStoeker, M. Genuardi, AT. Yeung, Y. Matsumoto, A. Bellacosa (2000) "Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch_specific DNA N_glycosylase." *J Biol Chem.* 275: 32422_9. 18. Petronzelli F, D. Sollima, G. Coppola, ME. Martini_Neri, G. Neri, M. Genuardi (2001) "CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred" *Genes Chromosomes Cancer.* 3: 398_401. 19. Viel, Petronzelli F, L. Della Puppa, E. Lucci Cordisco, M. Fornasari, S. Pucciarelli, V. Rovella, M. Quaia, M. Ponz de Leon, M. Boiocchi, M. Genuardi (2002) "Different molecular mechanisms underlie genomic deletions in the MLH1 gene". *Human Mutation*, in press. 20. R. De Santis, A.M. Anastasi, V. D'Alessio, A. Pelliccia, C. Albertoni, A. Rosi, B. Leoni, R. Lindstedt, Petronzelli F, M. Dani, A. Verdoliva, A. Ippolito, N. Campanile, V. Manfredi, A. Esposito, G. Cassani, M. Chinol, G. Paganelli, P. Carminati (2003) "Novel anti_tenascin antibody with increased tumor localization for Pretargeted Antibody Guided RadioImmunoTherapy (PAGRITR)" *Br. J. Cancer*, 88: 996_1003. 21. Shaw BE, Maldonado H, Madrigal JA, Smith C, Petronzelli F, Mayor NP, Potter MN, Bodmer JG, Marsh SGE (2004) Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor haematopoietic stem cell transplantation. *Tissue Antigens*, 63(5):401_11. 22. Petronzelli F, Pelliccia A, Anastasi AM, D'Alessio V, Albertoni C, Rosi A, Leoni B, De Angelis C, Paganelli G, Palombo G, Dani M, Carminati P, De Santis R. (2005) Improved tumor targeting by combined use of two antitenascin antibodies. *Clin Cancer Res.* 11:7137s_7145s. 23. Bellofiore P, Petronzelli F, De Martino T, Minenkova O, Bombardi V, Anastasi AM, Lindstedt R, Felici F, De Santis R, Verdoliva A. (2006) Identification and refinement of a peptide affinity ligand with unique specificity for a monoclonal anti_tenascin_C antibody by screening of a phage display library. *J Chromatogr A.* 1107:182_91. 24. Pavoni E, Flego M, Dupuis ML, Barca S, Petronzelli F, Anastasi AM, D'Alessio V, Pelliccia A, Vaccaro P, Monteriu G, Ascione A, De Santis R, Felici F, Cianfriglia M, Minenkova O. (2006) Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein. *BMC Cancer.* 6:41. 25. De Santis R, Albertoni C, Petronzelli F, Campo S, D'Alessio V, Rosi A, Anastasi AM, Lindstedt R, Caroni N, Arseni B, Chiodi P, Verdoliva A, Cassani G, Chinol M, Paganelli G, Carminati P. (2006) Low and high tenascin_expressing tumors are efficiently targeted by ST2146 monoclonal antibody. *Clin Cancer Res.* 12:2191_6. 26. E Pavoni, G Monteriu, D Santapaola, F Petronzelli, AM

Anastasi, A Pelliccia, V D'Alessio, R De Santis, O Minenkova (2007) Tumor_infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. *BMC Biotechnology*, 7:70 27. Lindstedt R., Ruggiero V., D'Alessio V., Manganello S., Petronzelli F., Stasi S., Vendetti S., Assandri A., Carminati P., De Santis R. (2009) The immunosuppressor ST1959 – a 3,5,_diaryl_S_ triazole derivative inhibits T cell activation by reducing NFAT nuclear residency. *Int J Immunopathol Pharmacol* 22(1): 29_42. 28. De Santis R., Albertoni C., Rosi A., Leoni B., Petronzelli F., D'Alessio V., Nucera E., Salvatori G., Paganelli G., Carminati P., Nuzzolo C.A. (2009) OXavidin for tissue targeting biotinylated therapeutics. *J Biomed Biotechnol*, 2009;2009:921434. Epub 2010 Jan 10. 29. Petronzelli F., Pelliccia A., Anastasi A.M., Lindstedt R.F., Manganello S., Ferrari L., Albertoni C., Leoni B., Rosi A., D'Alessio V., Deiana K., Paganelli G., De Santis R. (2010) Therapeutic use of avidin is not hampered by anti_avidin antibodies in humans. *Cancer Biother Radiopharm*, 25:563_70. 30. Pacchiana G, Cristina Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, Carminati P, Comoglio PM, Michieli P Vigna E. (2010) Monovalency unleashes the full therapeutic potential of the DN_30 anti_met antibody. *J Biol Chem*. 12;285(46):36149_57. 31. Petronzelli F, Anastasi AM, Pelliccia A, Santapaola D, Albertoni C, Rosi A, Leoni B, Ferrari L, Paganelli G, Gramiccioli G, Pesce D, Alfano AM, Stasi MA and De Santis R. (2011) Preclinical pharmacology and safety of a novel avidin derivative for tissue targeted delivery of radiolabeled biotin. *Basic Clin Pharmacol Toxicol*, 109:145_55. 32. De Santis R, Anastasi AM, Pelliccia A, Rosi A, Albertoni C, Verdoliva A, Petronzelli F, D'Alessio V, Serani S and Nuzzolo C. (2011) Chemical linkage to injected tissues is a distinctive property of oxidized avidin. *PLoS One*. 6(6):e21075. 33. De Santis R, Rosi A, Anastasi AM, Chiapparino C, Albertoni C, Leoni B, Pelliccia A, Santapaola D, Carollo V, Marra E, Aurisicchio L, Arseni B, Pacello ML, Palmieri G, Battella S, Petronzelli F and Milazzo FM. (2014) Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX_anchored biotinylated Cetuximab. *Oncotarget*. 5(19):9239_55. 34. Vigna E, Chiriaco C, Cignetto S, Fontani L, Basilio C, Petronzelli F and Comoglio PM. (2015) Inhibition of ligand_independent constitutive activation of the Met oncogenic receptor by the engineered chemically_modified antibody DN30. *Mol Oncol*. S1574_7891(15)00122_2. 35. Vesce L, Milazzo FM, Anastasi AM, Petronzelli F, Chiapparino C, Carollo V, Roscilli G, Marra E, Luberto L, Aurisicchio L, Pacello ML, Spagnoli LG and De Santis R. (2016) Intra_tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer. *Oncotarget*, 7(1):914_28. 36. Milazzo FM, Anastasi AM, Chiapparino C, Rosi A, Leoni B, Vesce L, Petronzelli F and De Santis R. (2017) AvidinOX_anchored biotinylated Trastuzumab and Pertuzumab induce down_modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not_anchored antibodies. *Oncotarget*, 8(14):22590_22605. 37. Gritti G, Gianatti A, Petronzelli F, De Santis R, Pavoni C, Rossi RL, Cattaneo L, Spagnoli LG, Ferrari S, Rossi A, Barbui AM and Rambaldi A (2018) Evaluation of Tenascin_C by Tenatumomab in Peripheral T_Cell Lymphoma Identifies a New Target for Radioimmunotherapy. *Oncotarget*, 9(11):9766_9775 38. Giannini G, Milazzo FM, Battistuzzi G, Rosi A, Anastasi AM, Petronzelli F, Albertoni C, Tei L, Leone L, Salvini L, De Santis R. (2019) Synthesis and preliminary in vitro evaluation of DOTA_Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. *Bioorg Med Chem*. 27(15):3248_3253 39. Moretti F, Gonella L, Gironi S, Marra AR, Santuccio C, Felicetti P, Petronzelli F, Marchione P, Barnaba SA, Poli A, Zaroni G, Moretti U. (2020) Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017. *Sci Rep*. 2020 Aug 24;10(1):14122. doi: 10.1038/s41598_020_70996_x. 40. Addis A, Genazzani A, Trotta MP, Magrini N; Italian Medicines Agency's Scientific Committee and COVID_19 Crisis Unit. (2020) Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID_19 Emergency in Italy. *Ann Intern Med*. 2020 Oct 20;173(8):654_655. doi: 10.7326/M20_3775. Epub 2020 Jun 16. 41. Massari M, Spila Alegiani S, Morciano C, Spuri M, Marchione P, Felicetti P, Belleudi V, Poggi FR, Lazzaretto M, Ercolanoni M, Clagnan E, Bovo E, Trifirò G, Moretti U, Monaco G, Leoni O, Da Cas R, Petronzelli F, Tartaglia L, Mores N, Zaroni G, Rossi P, Samez S, Zappetti C, Marra AR, Menniti Ippolito F; TheShinISS_Vax|COVID Surveillance Group (2022) Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID_19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi_database, self_controlled case series study. *PLoS Med*. 2022 Jul 28;19(7):e1004056. doi: 10.1371/journal.pmed.1004056. eCollection 2022 Jul. PMID: 35900992 42. Rafaniello C, Gaio M, Zinzi A, Sullo MG, Liguori V, Ferraro M, Petronzelli F, Felicetti P, Marchione P, Marra AR, Rossi F, De Angelis A, Capuano A. (2022) Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID_19 and Following mRNA COVID_19 Vaccines. *Pharmaceuticals (Basel)*. 2022 Apr 25;15(5):525. doi: 10.3390/ph15050525.PMID: 35631352

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)